Insurance Coverage and Paying for the Oncotype DX Test
Medicare has established coverage for the Oncotype DX Prostate Cancer test for qualified Medicare patients with early-stage prostate cancer.
Genomic Health believes that every eligible man should have access to the information they need to make confident, informed decisions about their cancer treatments. To help you with payment and reimbursement issues, Genomic Health provides comprehensive services to ease the reimbursement process for patients through the Genomic Access Program (GAP). GAP is for patients covered by a U.S. insurance company.
For more information about GAP, contact Genomic Health Customer Service at 855-677-6782 (855 6 PROSTATE).